Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
Healthcare
$2.34 -4.34%
-$0.11 today
- Market cap
- $441.63M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
52W Low $0.29High $3.11
Volume 1.77M
Average 3.07M
Income Statement
Follow revenue through to earnings.
Revenue
$7.25M
FY 2025 · Annual
+1181.3% YoYOperating Income
-$42.44M
FY 2025 · Annual
Net Income
-$17.41M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| 67.48M | 70.43M | 70.58M | 70.91M | 73.74M | |
| 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
OVID Earnings Waterfall · TTM
NASDAQ:OVID · Revenue to Net Income
Key Ratios
EPS$-0.35
Gross Margin75.0%
Net Margin-1984.9%
P/E Ratio-0.5
P/S Ratio222.4
Analysis
$7.1M of revenue converted into -$24.2M of net income for the selected period. Gross margin is 75.0% and net margin is -1984.9%, showing how much revenue survives after costs and taxes. EPS is $-0.35, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| S-3 | S-3 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does OVID generate?
Ovid Therapeutics Inc. (OVID) reported $7.25M of revenue in fiscal 2025.
Is OVID profitable?
Ovid Therapeutics Inc. (OVID) reported -$17.41M of net income, with a net margin of -240.1%.
Continue the stock analysis
Jump to another research area for this company.